Sucampo Pharmaceuticals submits supplemental new drug application for Lubiprostone to treat IBS-C
Sucampo Pharmaceuticals, Inc., (Sucampo Pharmaceuticals) today announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C). Lubiprostone, developed by Sucampo Pharmaceuticals, is currently approved for the treatment of C...Advances in understanding bipolar disorder topics of press briefings June 7, 8
... The Seventh Conference will be held June 7-9 at the David L. Lawrence Convention Center, in the heart of downtown Pittsburgh, and is being sponsored by the Uni...New study demonstrates that Lubiprostone may improve symptom relief rates in adults with IBS-C
... "In this study, patients receiving lubiprostone were nearly twice as likely to achieve an overall response from symptoms of IBS-C compared to those receiving placebo," said Douglas A. Drossman,...American College of Physicians commends introduction of Bipartisan Health CARE Act
... The endorsement was made by ACP president David C. Dale, MD, FACP at a Capitol Hill news conference. The co-sponsors, who outlined their proposal at Wednesdays news conference, introduced their measure to coincide with ACPs annual Leadership Day on Capitol Hill. Representatives Kaptur and LaTourette, who are both from...ACP enthusiastically supports introduction of Bipartisan Health CARE Act
... ... ... ... According to information from the Census Bureau, 44.8 million Americans lacked health coverage for all of 2005. Without insurance,...Animal BiP levels determine amount of recovery sleep needed following prolonged wakefulness
... The study, conducted by Nirinjini Naidoo, PhD, and co...Study sheds light on medication treatment options for bipolar disorder
... Bipolar disorder, a sometimes debilitating illness marked by severe mood swings b...UIC receives grant to find new drugs for bipolar disorder
... ... "Currently, treatments for bipolar disorder include so-called 'mood stabilizers' -- lithium and valproic acid," Kozikowski said. "Both are relatively dated drugs that...New gene linked to bipolar disorder
... ... Bipolar...Short episodes of manic symptoms may indicate bipolar disorder in some youth
... The res...Bipolar disorder exacts twice depression's toll in workplace
Bipolar disorder costs twice as much in lost productivity as major depressive disorder, a study funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH) has found. Each U.S. worker with bipolar disorder averaged 65.5 lost workdays in a year, compared to 27.2 for major depression. Even though major depression is more than six times as prevalent, bipolar disor...New treatment model for bipolar disorder shows promise
... ... "We ap...Study identifies predictors of bipolar disorder risk
Toronto, Canada, May 22, 2006 A new study presented today at the 159th Annual Scientific Meeting of the American Psychiatric Association (APA) in Toronto, Canada identified five predictors for bipolar disorder risk in patients who have been unsuccessfully treated with antidepressants. Researchers concluded that significant risk factors of bipolar disorder among patients already diagnosed with m...New study demonstrates that AMITIZA (lubiprostone) may help improve symptoms
A new study found that AMITIZA(TM) (lubiprostone) may help relieve the symptoms associated with constipation-predominant irritable bowel syndrome (IBS-C). IBS is a condition that affects nearly 30 million people in North America and accounts for 25-50 percent of referrals to gastroenterologists. The study was presented today at Digestive Disease Week, the largest annual meeting of digestive dis...AMITIZA(TM) (lubiprostone) shown effective and well-tolerated in people older than age 65
AMITIZA(TM) (lubiprostone), the first selective chloride channel activator for the treatment of chronic idiopathic constipation, was effective and well-tolerated in treating the symptoms of chronic idiopathic constipation in the elderly adult population according to findings presented during a poster session today at Digestive Disease Week 2006....... "AMITIZA is unique among prescription treatme...Best settings for biphasic automated defibrillators investigated
As the use of automated external defibrillation (AED) devices outside of hospital settings increases, the scientific medical community has not agreed on the optimal energy levels for initial and subsequent biphasic shocks. A study presented at the 2006 Society for Academic Emergency Medicine Annual Meeting, May 18-21, 2006 in San Francisco investigated both fixed and escalating biphasic energy re...AMITIZA (lubiprostone) launches in the United States
Bethesda, Md., and Lincolnshire, Il. Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc., announced today that AMITIZA (lubiprostone), 24-mcg soft-gel capsules, approved by the U.S. Food and Drug Administration (FDA) in January 2006, is now available by prescription in pharmacies across the United States for the treatment of chronic idiopathic constipation in adults. AMIT...Course of bipolar disorder in youths described for the first time
Children with bipolar disorder experience more enduring and rapidly changing symptoms of the disease than adults, according to a study that, for the first time, maps the clinical progression of each of the three sub-types of bipolar disorder in children and adolescents. The findings were published today by researchers from the University of Pittsburgh School of Medicine in the February issue of A...Yale findings hold promise for stopping progression of bipolar disorder
Changes in the brain that are important indicators of bipolar disorder are not prominent until young adulthood and are reduced in persons taking mood-stabilizing medications, Yale School of Medicine researchers report this month in Biological Psychiatry....... The researchers used magnetic resonance imaging to measure a part of the brain that regulates emotions, the ventral prefrontal cortex, tha...Bipolar disorder more common than expected in hospitalized adolescents
Clinicians at Bradley Hospital, the nation's first psychiatric hospital for children and adolescents, have found that bipolar disorder is more common than expected in teens in a psychiatric inpatient setting.... ... "In the past, mental health professionals thought that about one percent of teens was bipolar our research indicates that if a strict definition of the illness is applied, up to twen...Capsules effective in treating acute manic and mixed episodes of Bipolar I Disorder
Shire Pharmaceuticals Inc. has announced that University of North Carolina at Chapel Hill researchers studied the efficacy of carbamazepine extended-release capsules (CBZ-ERC, Equetro) in patients with manic or mixed episodes of Bipolar I Disorder over six months. Data from this open label study was presented by UNC researchers last week at the 18th annual U.S. Psychiatric and Mental Health Cong...New book on bipolar disorder targets 12 million affected Americans, families
... ... ...... Nearly 4 percent of adults in the United States almost 12 million people suffer from some version of bipolar disorder. Commonly referred to as manic-depressive illness, bipolar disorder is characterized by cycles of mania, depression or mixed emotional states that often disrupt work, school, family and social life. Recent revelations by popular television host Jane Pauley and f...Emotional impairment linked to cognitive deficits in bipolar children
Researchers at the University of Illinois at Chicago used functional brain imaging to establish a link between emotional impairment and poor cognition in children with bipolar disorder.... ..."This study is very exciting because it shows that negative emotions affect cognition differently than positive emotions in these kids," said Dr. Mani Pavuluri, associate professor of psychiatry at UIC's Ins...BOLDER II study confirms therapeutic potential of SEROQUEL in bipolar depression
Alderley Park, Cheshire, UK, 21 October 2005: - Newly released top-line results from the BOLDER II (BipOLar DEpRession) study have underlined the potential for SEROQUEL (quetiapine fumarate) in the treatment of patients with major depressive episodes associated with bipolar disorder. In BOLDER II, SEROQUEL 300mg and 600mg doses achieved a statistically significant reduction in levels of bipolar...One-drug therapy works for bipolar disorder
CLEVELAND -- For the first time, researchers have demonstrated in separate short-term trials that a single drug therapy may be effective in treating both the manic and depressive phases of bipolar disorder. The condition (bipolar I and II) affects approximately 8 million Americans, who have relied on a combination of drugs to manage their symptoms, and who remain at high risk of committing suici...Global survey reveals personal impact of bipolar disorder
Vienna, June 29th 2005 The World Federation for Mental Health (WFMH) today announced results of a global bipolar disorder consumer survey, Thinking Ahead, at the World Congress of Biological Psychiatry. The survey revealed that almost half (47%) of all people with bipolar disorder or 'consumers' as many mental health patients prefer to be referred to as feel that their disease has had a highly...Bipolar disorder more prevalent and costly than believed; Lithium could curb suicide rate
PITTSBURGH, June 17 The incidence of bipolar disorder in the general population is considerably higher than earlier studies have indicated, resulting in significantly less productivity and more days lost from work compared to the better known major depressive disorder, according to preliminary findings from a national survey presented today at the Sixth International Conference on Bipolar Disord...Bipolar disorder linked to specific brain regions; certain drugs alter brain metabolism
PITTSBURGH, June 17 Late-breaking research, including a study that identifies the specific regions of the brain that may be responsible for manic behaviors, will be presented in a special session at the Sixth International Conference on Bipolar Disorder, held June 16 to 18 at the David L. Lawrence Convention Center in Pittsburgh. ...... The special session includes 12 presentations that specifi...Search for bipolar gene, toll of disease topics of conference call briefings June 16, 17
PITTSBURGH, June 13 Held every two years, the International Conference on Bipolar Disorder is the only venue in the world devoted exclusively to highlighting new research into bipolar disorder, which affects both adults and children, devastates families and work relationships, accounts for nearly half of all suicides in the United States and costs billions in medical bills, missed work and lower...International conference on bipolar disorder June 16-18 a forum for new research
PITTSBURGH, June 1 New findings in clinical and basic science research will be presented for the first time at the Sixth International Conference on Bipolar Disorder, June 16-18, among them results of a national survey indicating bipolar disorder, commonly known as manic depression, is much more prevalent than previously believed.... ...More than 1,000 of the world's leading experts on bipolar d...New data show the efficacy of EQUETRO in patients with Bipolar I Disorder
Atlanta, Ga May 24, 2005 Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that EQUETROTM (carbamazepine extended-release capsules) are effective in significantly reducing the manic symptoms in patients with Bipolar I Disorder previously taking valproate or lithium, according to a pooled analysis of two phase 3 trials, one of two posters about carbamazepine ext...New Seroquel data support benefits in bipolar disorder
Alderley Park, UK May 24, 2005 New data presented today at the American Psychiatry Association (APA) meeting in Atlanta, USA, demonstrate that the atypical antipsychotic SEROQUEL (Quetiapine) is effective in reducing suicidal thinking in patients suffering from bipolar depression, and also improves quality of life and adherence to treatment in patients with bipolar disorder. ...... "Unfort...Data further examines Seroquel (quetiapine fumarate) treatment for bipolar depression
WILMINGTON, Del, Tuesday May 24 2005 AstraZeneca (NYSE: AZN) today announced additional findings at the annual meeting of the American Psychiatric Association (APA) from the BOLDER (BipOLar DEpRession) trial, a large-scale study that examined SEROQUEL as a treatment for depressive episodes in patients with bipolar I and II disorders. Results from this trial showed SEROQUEL (600 mg/day and 300 m...Media invited to international conference on bipolar disorder June 16-18 in Pittsburgh
PITTSBURGH, May 18 More than 1,000 researchers, clinicians and mental health advocates are expected to attend the Sixth International Conference on Bipolar Disorder ...June 16-18 at the David L. Lawrence Convention Center in Pittsburgh. New research will be presented covering the pathophysiology, assessment and treatment of bipolar illness, as well as on psychobiology, epidemiology and the psych...BETHESDA, MD April 1, 2005 Sucampo Pharmaceuticals, Inc., a leader in functional fatty acid research and development, today announced that it has submitted a new drug application (NDA) to the United States Food and Drug Administration (FDA) on March 31, 2005 to market lubiprostone, a novel compound with a unique mechanism of action, for the treatment of chronic idiopathic constipation (CIC) and...